Literature DB >> 23511694

Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients.

Albert Dahan1, Frank Overdyk, Terry Smith, Leon Aarts, Marieke Niesters.   

Abstract

BACKGROUND: Opioids may induce life-threatening respiratory depression, but limited knowledge is available on factors that contribute to opioid-induced respiratory depression (OIRD). This is especially true for patients with chronic pain on prolonged opioid therapy. There are no good quality case control studies or randomized controlled trials available on this topic. Here we present and analyze all case series since 1980 on OIRD in chronic pain patients extracted from PubMed.
OBJECTIVE: To describe and understand clinically identified factors involved in life-threatening OIRD in patients receiving opioids for chronic pain relief. STUDY
DESIGN: A literature search was performed for all relevant case reports on OIRD in chronic pain.
METHODS: We searched PubMed (www.ncbi.nlm.nih.gov) for all available case reports/series on OIRD in adolescent (12 years and older) and adult patients treated with opioids for chronic pain, from which we identified specific commonalities that contributed to OIRD (akin to closed claims analyses). The dataset was post-hoc divided into 2 distinct categories: cases published from 1980 to 1999 and those from 2000 to 2012.
RESULTS: Thirty-four reports describing 42 chronic pain patients experiencing OIRD were retrieved. Cases published before the year 2000 (pre-2000) predominantly involved morphine in cancer patients, whereas cases since 2000 (post-2000) predominantly involved methadone or transdermal fentanyl in non-cancer pain patients. Specific factors that contributed to OIRD were elevated opioid plasma levels due to renal impairment and sensory deafferentiation in pre-2000 cases, and elevated plasma levels due to drug interactions on the cytochrome P450 in post-2000 cases. LIMITATIONS: The case series analysis of published case reports imposes limitations in terms of the types of cases presented (only severe cases are published or cases with specific precipitating factors), the journal-related publication strategy, and changes in clinical practice.
CONCLUSIONS: Our case review confirms that life-threatening OIRD in chronic pain patients involves a series of complex often-interacting factors. In spite of the factors identified in this cases series, OIRD remains unpredictable and safe opioid prescribing requires careful titration of opioid dosages and continuous monitoring to prevent life-threatening OIRD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23511694

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  20 in total

1.  New Perspectives in the Treatment of Opioid-Induced Respiratory Depression.

Authors:  Loretta Fala; John A Welz
Journal:  Am Health Drug Benefits       Date:  2015-10

2.  AMPAkines and morphine provide complementary analgesia.

Authors:  Yongjun Sun; Kevin Liu; Erik Martinez; Jahrane Dale; Dong Huang; Jing Wang
Journal:  Behav Brain Res       Date:  2017-07-19       Impact factor: 3.332

3.  AMPAkines have novel analgesic properties in rat models of persistent neuropathic and inflammatory pain.

Authors:  Alexander M Le; Michelle Lee; Chen Su; Anthony Zou; Jing Wang
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

4.  Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study.

Authors:  Matthias Huber; Frank Andersohn; Giselle Sarganas; Elisabeth Bronder; Andreas Klimpel; Michael Thomae; Christine Konzen; Reinhold Kreutz; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2014-11-08       Impact factor: 2.953

5.  All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

6.  AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence.

Authors:  Xiaoyu Hu; Xuebi Tian; Xiao Guo; Ying He; Haijun Chen; Jia Zhou; Zaijie Jim Wang
Journal:  Neuropharmacology       Date:  2018-04-25       Impact factor: 5.250

7.  Inhibitory Effect of Endomorphin-2 Binding to the μ-Opioid Receptor in the Rat Pre-Bötzinger Complex on the Breathing Activity.

Authors:  Jian Qi; Hui Li; Ting-Bao Zhao; Ya-Cheng Lu; Ting Zhang; Jin-Lian Li; Yu-Lin Dong; Yun-Qing Li
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

8.  Recognition and response to opioid overdose deaths-New Mexico, 2012.

Authors:  Benjamin Levy; Bridget Spelke; Leonard J Paulozzi; Jeneita M Bell; Kurt B Nolte; Sarah Lathrop; David E Sugerman; Michael Landen
Journal:  Drug Alcohol Depend       Date:  2016-08-03       Impact factor: 4.492

Review 9.  Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding.

Authors:  Jan-Marino Ramirez; Nicholas J Burgraff; Aguan D Wei; Nathan A Baertsch; Adrienn G Varga; Helen A Baghdoyan; Ralph Lydic; Kendall F Morris; Donald C Bolser; Erica S Levitt
Journal:  J Neurophysiol       Date:  2021-04-07       Impact factor: 2.714

Review 10.  Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity.

Authors:  Brian A Baldo
Journal:  Arch Toxicol       Date:  2021-05-11       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.